/ CASE STUDIES

We passionately believe in the companies we fund and commit ourselves to transforming promising technologies into successful therapies.

/ CASE STUDY

Good Therapeutics, founded in 2016 by John Mulligan, Ph.D., was acquired by Roche in 2022 for $250 million upfront plus potential milestone payments. Even better, Mulligan and company retained their platform and the ability to mine it for innovative drugs to fight cancer and other diseases. 

/ CASE STUDY

RiverVest led the Series A investment in Standard Bariatrics in 2018. The surgical device company was acquired by Teleflex in 2022 for $170 million plus additional milestone payments.

/ CASE STUDY

Mirum was founded upon a drug compound that RiverVest helped develop through Lumena, a Fund II company acquired in 2014. After the acquirer deprioritized the drug, the Lumena team bought it back so they could finish what they started — getting kids with rare liver disease the relief they need.

/ CASE STUDY

RiverVest co-founded and seed funded Lumena and built a clinical strategy to fast-track its lead drug compound through clinical trials. The company was acquired by Shire in 2014.

Lumena-Image-1-800x564
rivervest map dots graphic image

RiverVest’s Footprint Increases Its Opportunity Set

St. Louis

101 S. Hanley Road, Suite 1850
St. Louis, MO 63105
Phone: (314) 726.6700

San Diego

10996 Torreyana Road, Suite 280
San Diego, CA 92121
Phone: (314) 726.6700

Cleveland

11000 Cedar Avenue
Cleveland, OH 44106
Phone: (216) 658.3982
RiverVest strives to improve the lives of patients, support entrepreneurs, and earn the trust of investors through science, strategy, and innovation. Contact us at info@rivervest.com
Transparency in Coverage Rule: To access the machine-readable files created and published by United Healthcare, please click here.
© Copyright 2024 RiverVest® All Rights Reserved. | Privacy Policy

Subscribe to our newsletter

Rivervest Contact